Abstract
BACKGROUND: Novel devices target different facets of amblyopia risk factors (ARFs). Through birefringence, the Rebion blinq assesses binocular foveation. The Adaptica 2WIN is a multiradial infrared photorefractor that also estimates ocular alignment. PDI Check is a forced-choice, dynamic near-vision game for the autostereoscopic Nintendo 3DS. METHODS: New and returning patients to a pediatric ophthalmology clinic had concomitant confirmatory exams after all three vision screens had been validated with ROC curves, Bland-Altman plots, and Alaska Blind Child Discovery ellipsoid grades. Exam outcomes were classified by ARF visual acuity, strabismus, binocularity, and refractive errors following the 2021 AAPOS guidelines and Bosque-Hunter rubric for the blinq. RESULTS: A total of 202 ethnically diverse students aged 10±4 (4-19) years, 33% treatment-naïve, had a high (58%) prevalence of ARFs. Linear logMAR visual acuity, intereye differences, stereo and three-cone color correlated well between PDI Check and exams. Mean score on the 2WIN matched sphero-cylinder exam with ellipsoid scoring was 2.1±1.5. For AAPOS 2021 refractive plus strabismus, sensitivity/specificity for PDI Check was 68%/59%, 2WIN 72%/95%, and blinq 87%/32%. For the amblyopia or strabismus rubric, PDI Check was 79%/68%, 2WIN 56%/65%, and blinq 94%/37%. CONCLUSION: Each device had advantages and disadvantages in screening this cohort of older, high-prevalence students, many of whom had already been treated. Validation methods should cover more than just refraction, as the new 2021 AAPOS guidelines do.